Dr. Tamer Coskun
Biography & Research Background
Tamer Coskun, MD, PhD, is a research scientist whose group published the discovery-to-clinical-proof-of-concept characterization of LY3437943 (retatrutide) in Cell Metabolism in 2022, and previously the corresponding characterization of the dual GIP/GLP-1 receptor agonist LY3298176. His work defines the receptor pharmacology that distinguishes triple agonism from dual and selective incretin agonism. Tamer Coskun is being referenced as one of the leading scientists involved in the research and development of retatrutide. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Cited In These Research Profiles (1)
Dr. Tamer Coskun is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Dr. Tamer Coskun is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.